Ultrasound contrast developer Acusphere has appointed a new chief development officer.
William Ramage, PhD, has more than 25 years of experience in cardiovascular imaging. He served as an executive consultant at Acusphere from March 2000 to October 2013, during which time he was responsible for key clinical and regulatory activities, according to the firm.
Prior to Acusphere, Ramage was vice president of business development and customer services at DuPont Merck (now Lantheus Medical Imaging) and had business responsibility for the nuclear perfusion agent Cardiolite and the ultrasound contrast agent Definity.
Acusphere is currently focused on the development of Imagify, a cardiovascular drug for the detection of coronary artery disease.
